SMMT logo

Summit Therapeutics Inc. Stock Price

NasdaqGM:SMMT Community·US$14.0b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 32 Fair Values set on narratives written by author

SMMT Share Price Performance

US$19.28
-1.98 (-9.31%)
US$19.28
-1.98 (-9.31%)
Price US$19.28

SMMT Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
2 Rewards

Summit Therapeutics Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$921.6m

Other Expenses

-US$921.6m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-1.24
0%
0%
0%
View Full Analysis

About SMMT

Founded
2003
Employees
159
CEO
Robert Duggan
WebsiteView website
www.smmttx.com

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Recent SMMT News & Updates

Recent updates

No updates